Analyst Puneet Souda from Leerink Partners maintained a Buy rating on Danaher (DHR – Research Report) and increased the price target to $230.00 from $225.00.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Puneet Souda has given his Buy rating due to a combination of factors that highlight Danaher’s strong market position and growth potential. Danaher is recognized as a leader in the bioprocess tools market, which is characterized by recurring revenue streams and high demand. The company has demonstrated consistent performance with seven consecutive quarters of order growth, indicating robust business momentum.
Despite some challenges such as tariff costs and a slight decline in the US academic segment, Danaher has shown resilience and adaptability. The management’s strategies to mitigate these challenges, along with the company’s strong position in the biotech sector, particularly in bioprocessing, bolster confidence in its future performance. Consequently, Souda sees Danaher as a high-quality investment with solid long-term growth prospects, justifying the Buy rating.
In another report released yesterday, Stifel Nicolaus also maintained a Buy rating on the stock with a $260.00 price target.
Based on the recent corporate insider activity of 68 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of DHR in relation to earlier this year.